We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CpG Oligodeoxynucleotides as TLR9 Agonists.
- Authors
Murad, Yanal M.; Clay, Timothy M.
- Abstract
Toll-like receptors (TLRs) are part of the innate immune system, and they belong to the pattern recognition receptors (PRR) family. The PRR family is designed to recognize and bind conserved pathogen-associated molecular patterns, which are not generated by the host and are restricted and essential to micro- organisms. TLR9, which recognizes unmethylated CpG (cytosine guanosine dinucleotide), is a very promising target for therapeutic activation. Stimulation of TLR9 activates human plasmacytoid dendritic cells and B cells, and results in potent T helper-1 (Th1)-type immune responses and antitumor responses in mouse tumor models and in patients. Several pharmaceutical companies, such as Pfizer, Idera, and Dynavax, are developing CpG oligo-deoxynucleotides (ODNs) for the treatment of cancer, along with other conditions, such as infections and allergy. CpG ODNs have shown promising results as vaccine adjuvants and in combination with cancer immunotherapy. Several TLR9 agonists are being developed and have entered clinical trials to evaluate their safety and efficacy for the treatment of several hematopoietic and solid tumors. In this review, we discuss the use of CpG ODNs in several phase I and II clinical trials for the treatment of NHL, renal cell carcinoma, melanoma, and non-small cell lung cancer, either alone or in combination with other agents.
- Subjects
IMMUNE system; CELL receptors; GUANOSINE triphosphatase; DENDRITIC cells; IMMUNE recognition; CANCER
- Publication
BioDrugs, 2009, Vol 23, Issue 6, p361
- ISSN
1173-8804
- Publication type
Article
- DOI
10.2165/11316930-000000000-00000